Taro Pharmaceutical Industries Ltd
NYSE:TARO
Taro Pharmaceutical Industries Ltd
NYSE:TARO
Price:
42.3 USD
-0.26%
Updated:
May 13, 2024
Taro Pharmaceutical Industries Ltd
Cost of Revenue
|
Taro Pharmaceutical Industries Ltd
Cost of Revenue Peer Comparison
Comparables:
T
TEVA
I
INCR
MDWD
R
REKA
C
CSURE
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Taro Pharmaceutical Industries Ltd
NYSE:TARO
|
Cost of Revenue
-$317.5m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-6%
|
|
T
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Cost of Revenue
-$7.9B
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
I
|
InterCure Ltd
TASE:INCR
|
Cost of Revenue
-₪265.3m
|
CAGR 3-Years
-146%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-63%
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Cost of Revenue
-$15.1m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Cost of Revenue
-₪235.6m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-3%
|
|
C
|
Cannassure Therapeutics Ltd
TASE:CSURE
|
Cost of Revenue
-₪30.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Taro Pharmaceutical Industries Ltd's Cost of Revenue?
Cost of Revenue
-317.5m
USD
-317.5m
USD
Based on the financial report for Dec 31, 2023, Taro Pharmaceutical Industries Ltd's Cost of Revenue amounts to -317.5m USD.
What is Taro Pharmaceutical Industries Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-6%
-6%
Over the last year, the Cost of Revenue growth was -6%. The average annual Cost of Revenue growth rates for Taro Pharmaceutical Industries Ltd have been -8% over the past three years , -8% over the past five years , and -6% over the past ten years .
You don't have any saved screeners yet
